Just hours after U.S. President Joe Biden was inaugurated, Janet Woodcock officially took the reins at the FDA. She will service as acting commissioner in an
Category: Pharmaceuticals
Novavax sees some COVID-19 vaccine trial dropout as Pfizer, Moderna rollouts gear up
As more supplies of Pfizer-BioNTech and Moderna’s authorized COVID-19 vaccines arrive, many states are expanding their reach beyond the elderly and into the 65-plus crowd.
Biden pledges to boost vaccine confidence—but how? Ad agency execs weigh in
As President Joseph Biden takes office today, organizing vaccine distribution and increasing vaccine supplies are day one priorities. But a bigger challenge to stemming the pandemic
GlaxoSmithKline PD-1 hopeful dostarlimab fell victim to COVID-related inspection delay: report
Many drugmakers last year fell victim to COVID-19 related FDA inspection delays that stalled drug approvals, and GlaxoSmithKline’s oncology hopeful dostarlimab was not immune, the British Big Pharma has revealed.
GlaxoSmithKline PD-1 hopeful dostarlimab fell victim to COVID-related inspection delay
Many drugmakers last year fell victim to COVID-19 related FDA inspection delays that stalled drug approvals, and GlaxoSmithKline’s oncology hopeful dostarlimab was not immune, the British Big Pharma has revealed.
Failure to launch? Half of drugs rolled out since 2004 didn’t live up to sales forecasts: report
The Nasdaq Biotechnology Index has risen more than 600% in the last 15 years, reflecting investor enthusiasm for a flood of novel drugs that Wall
While pandemic takes top priority for Biden, experts see favorable landscape for drug pricing action in Washington
Politicians of all stripes have run on promises to lower drug prices over the years, and outgoing President Donald Trump was no different. Fast-forward four years—past several
Fresenius Kabi pulls anti-inflammation drug Ketorolac over particulate fears—again
Fresenius Kabi’s manufacturing hiccups multiplied as 2020 unfolded. Now, a little more than a week into the new year, the German drugmaker found its way
Lonza to sell 2 plants to NextPharma as it plows ahead with $93M capsule expansion
Swiss CDMO Lonza put down a major down payment in October to boost capsule manufacturing by 15% across eight global sites. Now, it’s looking to
Lonza to sell two plants to NextPharma as it plows ahead with $93M capsule expansion
Swiss CDMO Lonza put down a major down payment in October to boost capsule manufacturing by 15% across eight global sites. Now, it’s looking to